In a wagon-circling move typical after Phase III setbacks such as befell Vical Inc.'s compound for metastatic melanoma earlier this month, the company said it will cut its work force by about 39 percent, or 47 employees, leaving 74 still aboard, as the Allovectin project is abandoned and efforts turn to infectious-disease vaccine programs.